alanine has been researched along with Carcinoma, Non-Small Cell Lung in 9 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our aim was to study gluconeogenesis from alanine in lung cancer patients and to analyze its relation to the degree of weight loss." | 9.09 | Weight loss and elevated gluconeogenesis from alanine in lung cancer patients. ( Dagnelie, PC; Hordijk-Luijk, CH; Leij-Halfwerk, S; van Den Berg, JW; Wattimena, JD; Wilson, JP, 2000) |
| "Our aim was to study gluconeogenesis from alanine in lung cancer patients and to analyze its relation to the degree of weight loss." | 5.09 | Weight loss and elevated gluconeogenesis from alanine in lung cancer patients. ( Dagnelie, PC; Hordijk-Luijk, CH; Leij-Halfwerk, S; van Den Berg, JW; Wattimena, JD; Wilson, JP, 2000) |
| "Treatment with gefitinib alone for chemotherapy-naïve NSCLC patients with EGFR mutations could achieve a high efficacy with acceptable toxicity." | 2.72 | Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. ( Fukuhara, T; Inoue, A; Kimura, Y; Maemondo, M; Morikawa, N; Nukiwa, T; Saijo, Y; Suzuki, T; Watanabe, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chiappori, AA | 1 |
| Creelan, B | 1 |
| Tanvetyanon, T | 1 |
| Gray, JE | 1 |
| Haura, EB | 1 |
| Thapa, R | 1 |
| Barlow, ML | 1 |
| Chen, Z | 1 |
| Chen, DT | 1 |
| Beg, AA | 1 |
| Boyle, TA | 1 |
| Castro, J | 1 |
| Morgan, L | 1 |
| Morris, E | 1 |
| Aregay, M | 1 |
| Hurtado, FK | 1 |
| Manenti, L | 1 |
| Antonia, S | 1 |
| Lu, YY | 1 |
| Huang, X | 1 |
| Luo, ZC | 1 |
| Qi, MY | 1 |
| Shan, JJ | 1 |
| Zhang, W | 1 |
| DI, LQ | 1 |
| Caiola, E | 1 |
| Colombo, M | 1 |
| Sestito, G | 1 |
| Lupi, M | 1 |
| Marabese, M | 1 |
| Pastorelli, R | 1 |
| Broggini, M | 1 |
| Brunelli, L | 1 |
| Yamauchi, M | 1 |
| Suzuki, K | 1 |
| Kodama, S | 1 |
| Watanabe, M | 1 |
| Inoue, A | 1 |
| Suzuki, T | 1 |
| Fukuhara, T | 1 |
| Maemondo, M | 1 |
| Kimura, Y | 1 |
| Morikawa, N | 1 |
| Watanabe, H | 1 |
| Saijo, Y | 1 |
| Nukiwa, T | 1 |
| Leij-Halfwerk, S | 4 |
| Dagnelie, PC | 3 |
| van Den Berg, JW | 3 |
| Wattimena, JD | 1 |
| Hordijk-Luijk, CH | 2 |
| Wilson, JP | 1 |
| Sijens, PE | 2 |
| Wilson, JH | 2 |
| Oudkerk, M | 2 |
| Agteresch, HJ | 1 |
| Dagneli, PC | 1 |
| Kappert, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC[NCT02403193] | Phase 1 | 92 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for alanine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Adenosine; Alanine; Antibodies, Monoclonal, Humanized; Aspartate Aminotransferases; Carcinoma, Non-S | 2022 |
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell | 2006 |
Weight loss and elevated gluconeogenesis from alanine in lung cancer patients.
Topics: Aged; Alanine; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Cross-Sectional Studies; Deuter | 2000 |
Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer.
Topics: Adenosine Triphosphate; Aged; Alanine; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, D | 2000 |
5 other studies available for alanine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
[Mechanism of Cordyceps militaris against non-small cell lung cancer: based on serum metabolomics].
Topics: Alanine; Animals; Arginine; Aspartic Acid; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cordyceps; Glu | 2022 |
Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation.
Topics: Alanine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Glutaminase; Humans; Lung Neoplasms | 2020 |
Stabilization of alanine substituted p53 protein at Ser15, Thr18, and Ser20 in response to ionizing radiation.
Topics: Alanine; Amino Acid Substitution; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Fibrosarcoma; Ge | 2004 |
Altered hepatic gluconeogenesis during L-alanine infusion in weight-losing lung cancer patients as observed by phosphorus magnetic resonance spectroscopy and turnover measurements.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Non-Small-Cell Lung; Female; Glucagon; Gluconeog | 2000 |
Decreased energy and phosphorylation status in the liver of lung cancer patients with weight loss.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Non-Small-Cell Lung; Ene | 2000 |